Give Kids a Chance Act of 2025
Sponsored By: Senator Markwayne Mullin
Introduced
Summary
The Give Kids a Chance Act of 2025 would _accelerate pediatric cancer drug development_ by clarifying when molecularly targeted pediatric investigations may be required, extending the rare pediatric disease priority review voucher program, and forcing FDA guidance plus multi-year oversight reviews.
Show full summary
- Families and children: Would push drug sponsors to generate age-appropriate formulations and pediatric data on dosing, safety, and early efficacy to support pediatric labeling. The pediatric study rules would apply to applications submitted three years after enactment.
- Drug developers: Would let FDA require studies of the submitted product alone or in combination with certain approved adult cancer drugs. Required combinations are limited to either a single new active ingredient or multiple ingredients already approved for adult cancers and FDA may ask for preclinical results with the initial pediatric study plan.
- Voucher program and oversight: Would extend the rare pediatric disease priority review voucher program to September 30, 2029 and require the voucher user fee when the voucher is used at application submission. It also mandates Comptroller General (GAO) studies and a GAO findings report to Congress to assess program effects five years after enactment.
Your PRIA Score
Personalized for You
How does this bill affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this bill and every other piece of legislation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Bill Overview
Analyzed Economic Effects
2 provisions identified: 0 benefits, 0 costs, 2 mixed.
New pediatric cancer study rules
This bill would let FDA require molecularly targeted pediatric cancer studies on a drug alone or in set drug combinations. Studies would have to use age-appropriate formulations and produce data on dosing, safety, and early effectiveness to inform pediatric labeling. The FDA must say which rule applies before a sponsor files its initial pediatric study plan. The FDA could also require preclinical study results with that plan. The new rules would apply to applications filed three years after enactment. If enacted, this could speed pediatric evidence but also add study requirements and workload for drug makers.
Rare pediatric drug voucher changes
This bill would extend the rare pediatric disease priority review voucher program through September 30, 2029. It would also require the priority review user fee to be paid when a drug application using a voucher is submitted. GAO would study the PRV program and report findings within about five years. If enacted, the extension preserves an incentive for developers but earlier fee timing could affect sponsors' cash flow.
Free Policy Watch
You just read the policy. Now see what it costs you.
Pick a topic. PRIA runs your household against live legislation and sends you a free personalized readout.
Pick a topic to get started
Sponsors & CoSponsors
Sponsor
Markwayne Mullin
OK • R
Cosponsors
Sen. Bennet, Michael F. [D-CO]
CO • D
Sponsored 3/11/2025
Amy Klobuchar
MN • D
Sponsored 4/4/2025
Sen. Shaheen, Jeanne [D-NH]
NH • D
Sponsored 4/4/2025
Sen. Marshall, Roger [R-KS]
KS • R
Sponsored 4/4/2025
Sen. Scott, Rick [R-FL]
FL • R
Sponsored 4/8/2025
Susan Collins
ME • R
Sponsored 4/8/2025
Sen. Coons, Christopher A. [D-DE]
DE • D
Sponsored 10/23/2025
Shelley Capito
WV • R
Sponsored 10/23/2025
Sen. Kelly, Mark [D-AZ]
AZ • D
Sponsored 10/23/2025
Sen. Husted, Jon [R-OH]
OH • R
Sponsored 10/23/2025
Andy Kim
NJ • D
Sponsored 10/23/2025
Sen. Sheehy, Tim [R-MT]
MT • R
Sponsored 10/23/2025
Sen. Moody, Ashley [R-FL]
FL • R
Sponsored 10/30/2025
John Hickenlooper
CO • D
Sponsored 10/30/2025
Tammy Duckworth
IL • D
Sponsored 11/6/2025
John Boozman
AR • R
Sponsored 11/6/2025
Sen. Schiff, Adam B. [D-CA]
CA • D
Sponsored 11/18/2025
Sen. Kennedy, John [R-LA]
LA • R
Sponsored 11/18/2025
Sen. Reed, Jack [D-RI]
RI • D
Sponsored 11/18/2025
Eric Schmitt
MO • R
Sponsored 11/19/2025
Roll Call Votes
No roll call votes available for this bill.
View on Congress.govTake It Personal
Get Your Personalized Policy View
Take the PRIA Score to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.
Already have an account? Sign in